Regencell Bioscience Holdings Ltd (RGC) - Total Assets
Based on the latest financial reports, Regencell Bioscience Holdings Ltd (RGC) holds total assets worth $5.76 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Regencell Bioscience Holdings Ltd (RGC) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Regencell Bioscience Holdings Ltd - Total Assets Trend (2003–2025)
This chart illustrates how Regencell Bioscience Holdings Ltd's total assets have evolved over time, based on quarterly financial data. See RGC total equity for net asset value and shareholders' equity analysis.
Regencell Bioscience Holdings Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Regencell Bioscience Holdings Ltd's total assets of $5.76 Million consist of 85.2% current assets and 14.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Regencell Bioscience Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RGC stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regencell Bioscience Holdings Ltd's current assets represent 85.2% of total assets in 2025, an increase from 16.8% in 2003.
- Cash Position: Cash and equivalents constituted 42.0% of total assets in 2025, up from 12.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 9.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Regencell Bioscience Holdings Ltd Competitors by Total Assets
Key competitors of Regencell Bioscience Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Livzon Pharmaceutical Group Inc
SHE:000513
|
China | CN¥24.19 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Canopy Growth Corp
TO:WEED
|
Canada | CA$1.11 Billion |
|
LAVIPHARM S.A. NA EO 1
F:BXA0
|
Germany | €125.48 Million |
Regencell Bioscience Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.39 | 34.02 | 0.09 |
| Quick Ratio | 7.39 | 34.81 | 0.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.24 Million | $6.39 Million | $-3.28 Million |
Regencell Bioscience Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Regencell Bioscience Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3169.23 |
| Latest Market Cap to Assets Ratio | 530.95 |
| Asset Growth Rate (YoY) | -31.8% |
| Total Assets | $5.76 Million |
| Market Capitalization | $3.06 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Regencell Bioscience Holdings Ltd's assets at a significant premium (530.95x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Regencell Bioscience Holdings Ltd's assets decreased by 31.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Regencell Bioscience Holdings Ltd (2003–2025)
The table below shows the annual total assets of Regencell Bioscience Holdings Ltd from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $5.76 Million | -31.79% |
| 2024-06-30 | $8.44 Million | -33.15% |
| 2023-06-30 | $12.62 Million | -29.95% |
| 2022-06-30 | $18.02 Million | +5197.59% |
| 2021-06-30 | $340.13K | -33.83% |
| 2020-06-30 | $514.02K | +111.26% |
| 2019-06-30 | $243.31K | -99.99% |
| 2018-06-30 | $2.84 Billion | +7.45% |
| 2017-06-30 | $2.65 Billion | +0.51% |
| 2016-06-30 | $2.63 Billion | +3.65% |
| 2015-06-30 | $2.54 Billion | -6.11% |
| 2014-06-30 | $2.70 Billion | +22.41% |
| 2013-06-30 | $2.21 Billion | -5.63% |
| 2012-06-30 | $2.34 Billion | -6.07% |
| 2011-06-30 | $2.49 Billion | -5.50% |
| 2010-06-30 | $2.64 Billion | +1.49% |
| 2009-06-30 | $2.60 Billion | -1.33% |
| 2008-06-30 | $2.63 Billion | +6.73% |
| 2007-06-30 | $2.47 Billion | -2.53% |
| 2006-06-30 | $2.53 Billion | -0.39% |
| 2005-06-30 | $2.54 Billion | +2.87% |
| 2004-06-30 | $2.47 Billion | +6.97% |
| 2003-06-30 | $2.31 Billion | -- |
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more